We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

MESS-study MRSA Eradication Study Skåne (MESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01269541
Recruitment Status : Completed
First Posted : January 4, 2011
Last Update Posted : August 22, 2017
Information provided by (Responsible Party):
Region Skane

Brief Summary:
The purpose of this study is to determine whether systemic antibiotic treatment with rifampicin and clindamycine or trimethoprim-sulfa in addition to topical treatment with mupirocin is more effective than only topical treatment to eradicate MRSA in throatcarriers

Condition or disease Intervention/treatment
Throatcarriers of MRSA Drug: Mupirocin Drug: Rifampin+Clindamycine or Trimehoprimsulfa

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: MESS- MRSA Eradication Study Skåne. A Comparison Between Systemic Antibiotic Treatment in Combination With Topical Mupirocintreatment With Only Topical Mupiroicintreatment to Eradicate MRSA in Throat Carriers
Actual Study Start Date : March 1, 2011
Primary Completion Date : May 1, 2015
Study Completion Date : May 1, 2015

Arm Intervention/treatment
Active Comparator: Mupirocin
Topical treatment
Drug: Mupirocin
Topical in the nose 3 times daily for 5 days
Drug: Rifampin+Clindamycine or Trimehoprimsulfa
Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
Active Comparator: Rifampicin+Clindamycine or Trimethoprimsulfa
Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2
Drug: Rifampin+Clindamycine or Trimehoprimsulfa
Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2

Primary Outcome Measures :
  1. Culture for MRSA [ Time Frame: after 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Colonized with MRSA in the throat Older than 5 years MRSA-bacteria sensitive for Rifampicin and Clindamycine or Trimethoprimsulfa -

Exclusion Criteria:

Allergy to the studymedication Healthcareworkers Pregnancy Active infection with MRSA Immunosuppression Treatment with other antibiotic during the studyperiod

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01269541

Helsingborg hospital
Helsingborg, Skåne, Sweden
Kristianstad hospital
Kristianstad, Skåne, Sweden
Infectious department SUS Lund
Lund, Skåne, Sweden
SUS Malmö
Malmö, Skåne, Sweden
Karolinska university hospital
Stockholm, Sweden
Örebro university hospital
Örebro, Sweden
Sponsors and Collaborators
Region Skane
Principal Investigator: Eva Melander, MD PHD Labmedicin Skåne Malmö

Responsible Party: Region Skane
ClinicalTrials.gov Identifier: NCT01269541     History of Changes
Other Study ID Numbers: MRSA-2010
2010-019727-55 ( EudraCT Number )
First Posted: January 4, 2011    Key Record Dates
Last Update Posted: August 22, 2017
Last Verified: May 2015

Additional relevant MeSH terms:
Clindamycin palmitate
Clindamycin phosphate
Trimethoprim, Sulfamethoxazole Drug Combination
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers
Protein Synthesis Inhibitors
Anti-Infective Agents, Urinary
Renal Agents
Antiprotozoal Agents
Antiparasitic Agents